Abstract

BackgroundStandard radiotherapy is the treatment of first choice in patients with symptomatic spinal metastases, but is only moderately effective. Stereotactic body radiation therapy is increasingly used to treat spinal metastases, without randomized evidence of superiority over standard radiotherapy. The VERTICAL study aims to quantify the effect of stereotactic radiation therapy in patients with metastatic spinal disease.Methods/designThis study follows the ‘cohort multiple Randomized Controlled Trial’ design. The VERTICAL study is conducted within the PRESENT cohort. In PRESENT, all patients with bone metastases referred for radiation therapy are enrolled. For each patient, clinical and patient-reported outcomes are captured at baseline and at regular intervals during follow-up. In addition, patients give informed consent to be offered experimental interventions. Within PRESENT, 110 patients are identified as a sub cohort of eligible patients (i.e. patients with unirradiated painful, mechanically stable spinal metastases who are able to undergo stereotactic radiation therapy). After a protocol amendment, also patients with non-spinal bony metastases are eligible. From the sub cohort, a random selection of patients is offered stereotactic radiation therapy (n = 55), which patients may accept or refuse. Only patients accepting stereotactic radiation therapy sign informed consent for the VERTICAL trial. Non-selected patients (n = 55) receive standard radiotherapy, and are not aware of them serving as controls. Primary endpoint is pain response after three months. Data will be analyzed by intention to treat, complemented by instrumental variable analysis in case of substantial refusal of the stereotactic radiation therapy in the intervention arm.DiscussionThis study is designed to quantify the treatment response after (stereotactic) radiation therapy in patients with symptomatic spinal metastases. This is the first randomized study in palliative care following the cohort multiple Randomized Controlled Trial design. This design addresses common difficulties associated with classic pragmatic randomized controlled trials, such as disappointment bias in patients allocated to the control arm, slow recruitment, and poor generalizability.Trial registrationThe Netherlands Trials Register number NL49316.041.14. ClinicalTrials.gov registration number NCT02364115. Date of trial registration February 1, 2015.

Highlights

  • Standard radiotherapy is the treatment of first choice in patients with symptomatic spinal metastases, but is only moderately effective

  • VERTICAL randomized controlled trial comparing conVEntional RadioTherapy with stereotactIC body radiotherapy in patients with spinAL metastases; PRESENT Prospective Evaluation of interventional StudiEs on boNe meTastases (PRESENT) cohort; Magnetic resonance imaging (MRI) magnetic resonance imaging; Stereotactic body radiotherapy (SBRT) stereotactic body radiotherapy; EBRT external beam radiotherapy; KPS Karnofsky performance score aradiculopathy, dermatomal sensory change, and muscle strength of involved extremity is Medical Research Counsil (MRC) 4/5 bon a scale from 0 to 10 nor will they be informed about their participation in the control arm of the VERTICAL study

  • We investigate whether SBRT can increase the proportion of patients with pain response

Read more

Summary

Discussion

We present the rationale and design of the VERTICAL trial. In this randomized study, we investigate whether SBRT can increase the proportion of patients with (complete or partial) pain response. Two other trials require both CT and MRI imaging for the delineation of the spinal metastases [37, 38], these trials delineate the whole bony compartment (i.e. the CTV) that contains the metastasis instead of using an simultaneous integrated boost approach They have strict instructions on how to apply the standard and stereotactic body radiotherapy in contrast to our more pragmatic approach, offering radiation oncologists leeway in fractionation schedule. The VERTICAL study is a pragmatic randomized trial, following the cmRCT design, which compares stereotactic radiotherapy with standard radiotherapy in patients with spinal metastases in terms of pain response, with the ultimate goal to improve quality of life

Background
Methods/design
Findings
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call